TY - JOUR
T1 - Predictors of patient self-ratings of quality of life in Alzheimer disease
T2 - Cross-sectional results from the Canadian Alzheimers disease quality of life study
AU - Naglie, Gary
AU - Hogan, David B.
AU - Krahn, Murray
AU - Beattie, B. Lynn
AU - Black, Sandra E.
AU - MacKnight, Chris
AU - Freedman, Morris
AU - Patterson, Christopher
AU - Borrie, Michael
AU - Bergman, Howard
AU - Byszewski, Anna
AU - Streiner, David
AU - Irvine, Jane
AU - Ritvo, Paul
AU - Comrie, Janna
AU - Kowgier, Matthew
AU - Tomlinson, George
PY - 2011/10
Y1 - 2011/10
N2 - Objectives: To assess whether the core symptoms of Alzheimer disease (AD) consistently predict patient self-rated quality of life (QOL) as assessed by a variety of QOL measures in a large national sample of AD patients. Design: Cross-sectional. Setting: Fifteen dementia and geriatric clinics across Canada. Participants: Community-living patients with AD (n = 370) with Mini-Mental State Exam (MMSE) scores greater than 10. Measurements: Patients rated their QOL by using two utility indexes, the European QOL-5 Dimensions and the Quality of Well-Being Scale, a global QOL Visual Analog Scale, and the disease-specific QOL-AD instrument. Cognition was assessed with the AD Assessment Scale-Cognitive subscale and MMSE, function with the Disability Assessment for Dementia, and behavioral and psychological symptoms with the Neuropsychiatric Inventory and the Geriatric Depression Scale (GDS). One-way analysis of variance and fully adjusted multiple linear regression were used to assess the relationship between core dementia symptoms and QOL ratings. Results: The QOL measures had only small-to-moderate correlations with each other. For all QOL measures, patient ratings were significantly lower among patients with more depressive symptoms. In multivariable analyses, the GDS score was the only significant independent predictor of patient self-ratings for all four QOL measures. Conclusions: Self-rated symptoms of depression were a consistent independent predictor of patient-rated QOL across diverse QOL measures, while performance-based measures of cognition and informant-based functional status were not. These findings confirm the importance of identifying and treating depression in patients with AD and endorse the use of measures of self-rated depressive symptoms and QOL as outcomes in AD clinical trials.
AB - Objectives: To assess whether the core symptoms of Alzheimer disease (AD) consistently predict patient self-rated quality of life (QOL) as assessed by a variety of QOL measures in a large national sample of AD patients. Design: Cross-sectional. Setting: Fifteen dementia and geriatric clinics across Canada. Participants: Community-living patients with AD (n = 370) with Mini-Mental State Exam (MMSE) scores greater than 10. Measurements: Patients rated their QOL by using two utility indexes, the European QOL-5 Dimensions and the Quality of Well-Being Scale, a global QOL Visual Analog Scale, and the disease-specific QOL-AD instrument. Cognition was assessed with the AD Assessment Scale-Cognitive subscale and MMSE, function with the Disability Assessment for Dementia, and behavioral and psychological symptoms with the Neuropsychiatric Inventory and the Geriatric Depression Scale (GDS). One-way analysis of variance and fully adjusted multiple linear regression were used to assess the relationship between core dementia symptoms and QOL ratings. Results: The QOL measures had only small-to-moderate correlations with each other. For all QOL measures, patient ratings were significantly lower among patients with more depressive symptoms. In multivariable analyses, the GDS score was the only significant independent predictor of patient self-ratings for all four QOL measures. Conclusions: Self-rated symptoms of depression were a consistent independent predictor of patient-rated QOL across diverse QOL measures, while performance-based measures of cognition and informant-based functional status were not. These findings confirm the importance of identifying and treating depression in patients with AD and endorse the use of measures of self-rated depressive symptoms and QOL as outcomes in AD clinical trials.
UR - http://www.scopus.com/inward/record.url?scp=80053279538&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80053279538&partnerID=8YFLogxK
U2 - 10.1097/JGP.0b013e3182006a67
DO - 10.1097/JGP.0b013e3182006a67
M3 - Article
AN - SCOPUS:80053279538
SN - 1064-7481
VL - 19
SP - 881
EP - 890
JO - American Journal of Geriatric Psychiatry
JF - American Journal of Geriatric Psychiatry
IS - 10
ER -